NCT04535713View on ClinicalTrials.gov

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Sarcoma
Interventions
DRUG

Gemcitabine

600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+

DRUG

Doxorubicin

18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+

DRUG

Docetaxel

25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+

DRUG

Nivolumab

240 mg i.v. on Day 1 beginnning Cycle 2+

Trial Locations (1)

90403

RECRUITING

Sant P Chawla, Santa Monica

All Listed Sponsors
lead

Sarcoma Oncology Research Center, LLC

OTHER